Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Change in Acquisitions & Divestments (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Change in Acquisitions & Divestments data on record, last reported at $60.0 million in Q4 2020.

  • For Q4 2020, Change in Acquisitions & Divestments rose 71.43% year-over-year to $60.0 million; the TTM value through Dec 2020 reached $131.0 million, changed N/A, while the annual FY2024 figure was $95.0 million, 42.01% down from the prior year.
  • Change in Acquisitions & Divestments reached $60.0 million in Q4 2020 per KLRS's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $60.0 million in Q4 2020 and bottomed at $6.0 million in Q3 2020.